Dexamethasone Reduces Nausea and Vomiting but not Pain after Thyroid Surgery: A Meta-Analysis of Randomized Controlled Trials

Bo Li, Huixia Wang

Background: Postoperative nausea and vomiting (PONV) is a common complication after thyroidectomy. The aim of this article was to evaluate the efficacy of dexamethasone for prevention of PONV and pain in patients undergoing thyroidectomy.

Material/Methods: We performed this meta-analysis based on the QUORUM (Quality of Reporting of Meta-analyses) guidelines. Our study included randomized controlled trials (RCTs) that compared preoperative single-dose administration of dexamethasone with no dexamethasone in patients undergoing thyroidectomy. The primary outcome was occurrence and severity of PONV, and the secondary outcomes included pain, use of analgesics, and steroid-related complications.

Results: Seven RCTs were included, with a total of 611 patients. A statistically and clinically significant difference in the incidence and severity of PONV was found in favor of dexamethasone (SMD, 0.23; 95% CI, 0.13–0.41; P<0.00001; SMD, 0.53; 95% CI, –1.03 to –0.03; P=0.04). However, there was no significant difference in reduction of pain severity and analgesic consumption in using dexamethasone (SMD, –0.83; 95% CI, –1.85 to 0.18; P=0.14; SMD, –0.19; 95% CI, –0.43 to 0.04; P=0.10). No steroid-related complications were noted.

Conclusions: A single preoperative administration of dexamethasone reduced the incidence and severity of PONV but not pain severity and analgesic consumption in patients undergoing thyroidectomy. Further studies with a larger sample size are needed to further explore the efficacy of dexamethasone on postoperative pain severity and analgesic consumption.

MeSH Keywords: Anesthesiology • Dexamethasone • Thyroidectomy

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/891390
Background

Thyroidectomies are one of the most common elective surgical procedures all over the world [1]. After thyroidectomy the incidence of postoperative nausea and vomiting (PONV), which is less than 30% in other surgical interventions [2], is 70–80% when no prophylactic antiemetic therapy is given [3,4]. PONV might be the main source of discomfort after thyroidectomy, and repeated or vigorous vomiting can lead to postoperative bleeding with subsequent airway obstruction and potential need for reparative surgery [5]. Apfel et al. found that patients were more afraid of PONV than postoperative pain, which substantiated the importance of avoiding PONV events [6]. Numerous antiemetics have been studied for the prevention and treatment of PONV following thyroidectomy, including tropisetron and dexamethasone [7,8]. Most published trials indicated improved prophylaxis against PONV by using effective antiemetic therapy in patients scheduled for thyroid surgery [1].

Postoperative pain and PONV are separate outcomes; however, it is well-recognized that pain can result in anxiety, which can be associated with nausea [9]. Interestingly, several studies have also shown that preoperative administration of steroids reduced postoperative pain after oral, orthopedic, spinal, and laparoscopic surgery [10–12].

Dexamethasone, an adrenocortical steroid, is effective in preventing the nausea and vomiting associated with cancer chemotherapy [13,14] and has shown efficacy against postoperative nausea in several studies [15–20]. Previous meta-analyses concluded that dexamethasone prophylactic use of steroids for patients undergoing thyroidectomy was safe and should be considered for routine clinical practice [21]. However, it failed to show the efficacy of dexamethasone on severity of PONV, and the data on pain relief was insufficient. In addition, a recent randomized trial by Barros et al. showed that dexamethasone did not have any effects on incidence of PONV [22]. Hence, the results reported on the use of dexamethasone for patients undergoing thyroidectomy are still variable and controversial. The objective of this study was to perform a meta-analysis to assess the overall effect of dexamethasone on PONV and pain after thyroidectomy.

Material and Methods

We performed this meta-analysis based on the QUORUM guidelines (Quality of Reporting of Meta-analyses) [23] and the recommendations of the Cochrane Collaboration [24].

Data sources and searches

The electronic databases screened were PubMed (1990 to February 2014), EMBASE (1990 to February 2014), and the Cochrane Library (Issue 1 of 12, Jan 2014), including the Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), and Health Technology Assessments (HTA). The search terms were: “thyroidectomy” or “thyroid surgery” AND “dexamethasone” or “steroid”. Searches were limited to randomized controlled trials in English and were performed for all types of publications. We also screened the references of retrieved articles and contacted the authors to request additional data when key information relevant to the meta-analysis was missing. The full search strategy was developed from PubMed and was adapted for the other electronic databases (Figure 1).

Data extraction

Two of us (BS Lv and W Wang) independently screened the titles and abstracts of potentially eligible studies. The full text articles were examined independently by 2 of us (BS Lv and W Wang) to determine whether they met the inclusion criteria. Two of us (BS Lv and W Wang) independently extracted data (study characteristics and results) using data extraction forms, and then the collected data were entered into RevMan 5.1 using the double-entry system. Point estimates for selected variables were extracted and checked by the other 2 reviewers. All discrepancies were rechecked and consensus was achieved by discussion. A record of reasons for excluding studies was kept. We selected PONV and pain symptoms as outcome measures for dexamethasone therapy. The primary outcome was occurrence and severity of PONV, and the secondary outcomes included pain, use of analgesics, and steroid-related complications. The Jadad test (5 items) [25] was applied for assessing methodological quality as high (score 5), moderate (score 4), or low (scores 1–3).
Data collection and analysis

The following data and information were collected:
1. General study information such as title, authors, contact address, publication source, publication year, country, and study sponsor.
2. Characteristics of the study: design, study setting, inclusion and exclusion criteria, quality criteria (e.g., randomization method, allocation procedure, blinding of patients, caregivers and outcome assessors, withdrawals and dropouts, and intention-to-treat (ITT) analysis whenever necessary).
3. Characteristics of the intervention, such as treatment comparators and duration of therapy.
4. Outcome measures as mentioned above.
5. Outcome measures at the end of the controlled phase, and any summary measures with standard deviations, confidence intervals, and P values, where given, dropout rate, and reasons for withdrawal.

Table 1. Characteristics of the trials included in the meta-analysis.

| Source           | Dose | Sample size | Anesthetic technique | Additional drug administration | Method quality | Outcome measures used for meta-analysis |
|------------------|------|-------------|----------------------|--------------------------------|----------------|----------------------------------------|
| Wang 1999 (Taiwan) | 10 mg | 38 De       | Propofol 2.0–2.5 mg/kg, glycopyrrolate 0.2 mg, fentanyl 2.0 µg/kg IV maintained with isoflurane in oxygen | Analgesia: diclofenac 75 mg IM Antiemetics: ondansetron 4 mg IV | 5              | Incidence of PONV Pain Score           |
| Lee 2001 (Taiwan)  | 8 mg vs. 5 mg | 88 De 44 P | Glycopyrrolate 0.2 mg, fentanyl 2.0 µg/kg, thiopental 5 mg IV maintained with desflurane in oxygen | Analgesia: ketorolac 15 mg IV Antiemetics: droperidol 1.25 mg IV | 5              | Incidence of PONV Pain Score           |
| Fujii 2007 (Japan) | 8 mg vs. 4 mg | 50 De 25 P | Propofol 2.0 mg/kg, fentanyl 2.0 µg/kg, vecuronium 0.1 mg/kg IV maintained with 1–3% sevoflurane in oxygen | Analgesia: indomethacin 50 mg rectally Antiemetics: oral ranitidine 150 mg | 4              | Incidence of PONV Severity of nausea  |
| Worni 2008 (Switzerland) | 8 mg | 37 De 35 P | Propofol/ thiopental, atracurium, isoflurane, or sevoflurane and fentanyl (5–10 µg/kg) | Analgesia: acetaminophen 4 g/day Antiemetics: ondansetron 4 mg IV | 5              | Incidence of PONV Severity of nausea Pain score Analgesic consumption |
| Feroci 2011 (Italy) | 8 mg | 51 De 51 P | Propofol 2 mg/kg, fentanyl 2 µg/kg, vecuronium 0.1 mg/kg IV maintained with sevoflurane in oxygen | Analgesia: paracetamol 1,000 mg IV q8 h, ketorolac 30 mg IV Antiemetics: metoclopramide 10 mg IV | 5              | Incidence of PONV Severity of nausea Pain score Analgesic consumption |
| Doksrod 2012 (Norway) | 0.3 mg/kg vs. 0.15 mg/kg | 80 De 40 P | Propofol, fentanyl, vecuronium IV maintained with desflurane in oxygen | Analgesia: fentanyl 0.5 µg/kg IV Antiemetics: metoclopramide 20 mg IV | 5              | Incidence of PONV Pain score Analgesic consumption |
| Barros 2013 (Portugal) | 4 mg | 17 De 17 P | Propofol 2 mg/kg, fentanyl 2 µg/kg, cimatracurium 0.15 mg/kg IV maintained with sevoflurane in oxygen | Analgesia: ketorolac 30 mg IV Antiemetics: ondansetron 4 mg IV | 5              | Incidence of PONV Severity of nausea Pain score Analgesic consumption |

De – dexamethasone; P – placebo; IV – intravenous; IM – intramuscular; PONV – postoperative nausea and vomiting; A – analgesia.
null
Effects model was used to evaluate the severity of PONV. According to Cohen categories for evaluating the magnitude of effect sizes, there was strong evidence for reducing incidence of PONV. Based on Cohen categories for evaluating the magnitude of effect sizes, there was no significant difference for a reduction of pain severity in using dexamethasone (SMD, 0.53; 95% CI, –1.03 to –0.03; P=0.04) (Figure 3), based on Cohen categories for evaluating the magnitude of effect sizes.

Pain severity

According to $\chi^2$ test of heterogeneity ($I^2=77\%$), a random-effects model was used to evaluate the severity of PONV. There was strong evidence for a reduction of PONV severity in using dexamethasone (SMD, 0.83; 95% CI, –0.83 to 0.18; P=0.14) (Figure 4).
Analgesic consumption

According to $\chi^2$ test of heterogeneity ($I^2=59\%$), a random-effects model was used to evaluate the severity of pain. There was no significant difference in reduction of analgesic consumption in using dexamethasone (SMD, $-0.19; 95\%$ CI, $-0.43$ to $0.04; P=0.10$) (Figure 5), based on Cohen categories for evaluating the magnitude of effect sizes.

Adverse events with dexamethasone therapy

No postoperative wound infections or steroid-related adverse events were noted in any of the included studies.

Risk of bias in included studies

Assessment tables of the risk of bias are presented in Figure 6A and Figure 6B. There was only 1 study, by Fujii et al., with moderate quality (score 4) because of the unclear reporting bias [17]. Sensitivity analysis was applied by excluding the study of Fujii et al. Based on Cohen categories for evaluating the magnitude of effect sizes, there was strong evidence for reducing incidence of PONV in using dexamethasone (SMD, $0.22; 95\%$ CI, $0.12$ to $0.43; P<0.00001$) (Figure 7).

Discussion

In 2012, the systematic review conducted by Chen et al. showed that a single preoperative administration of dexamethasone
To date, 7 randomized control trials have been published investigating the effects of a single-dose application of dexamethasone during thyroidectomy [15–20,22], and most of them support the use of dexamethasone.

Pain after thyroidectomy is another major cause of discomfort, and all patients experienced throat pain without other relevant pain. The recent review by De Oliveira et al. concluded that dexamethasone at doses more than 0.1 mg/kg is an effective adjunct in multimodal strategies to reduce post-operative pain and opioid consumption after surgery [32]. Furthermore, Chen et al. found evidence that dexamethasone significantly reduced the severity of postoperative pain and was more effective than placebo for reducing the use of analgesics [21]. However, 2 more recent RCTs by Doksrød et al. and Barros et al. reported no beneficial effect of a preoperative single dexamethasone dose on decreasing tramadol requirement after thyroid surgery [20,22], perhaps due to low sensitivity of the pain model or because pain after thyroid surgery responds poorly to glucocorticoid therapy [20]. In addition, Barros et al. concluded that their study results did not support the hypothesis that a preoperative single dexamethasone dose decreases tramadol requirement, possibly because the dexamethasone dose (4 mg) was too low [22]. Thus, they suggested that larger studies using a higher dexamethasone dose (8 mg) to analyze its beneficial effect on tramadol consumption are needed for further investigation [22].

In the present meta-analysis, the dosage of dexamethasone from included studies ranged from 5 mg to 10 mg. The study reduced the incidence of PONV and analgesic requirements in patients undergoing thyroidectomy [21]. However, the subsequent randomized trial by Doksrød et al. noted that dexamethasone had no analgesic or opioid-sparing effect in patients after thyroid surgery [20]. Our systematic review is remarkably different from the previous one and we assessed that: i) In addition to the previous meta-analysis, we have paid more attention to evaluating the severity of PONV; and ii) We included more studies, which included sufficient data on pain relief. Our current data showed that a single preoperative administration of dexamethasone reduced the incidence and severity of PONV but not pain severity and analgesic consumption in patients undergoing thyroidectomy.

PONV is an unpleasant experience after thyroidectomy, which might be perceived as the main source of discomfort in postoperative recovery [29]. However, the exact etiology of PONV after thyroidectomy is not clearly understood. It is assumed that several factors, including age, sex, and the intense of preoperative vagal stimulation might be related to PONV [30]. Other factors, including obesity, menstruation, smoking, and anesthetic technique, are considered to influence the frequency of PONV [31]. However, in all of the included randomized control trials the above factors were similar between experimental and control groups. Therefore, the difference in frequency of PONV among groups can be attributed to the drug tests.

Wang et al. did the first randomized controlled trial and showed efficacy against PONV in women undergoing thyroidectomy. To date, 7 randomized control trials have been published investigating the effects of a single-dose application of dexamethasone during thyroidectomy [15–20,22], and most of them support the use of dexamethasone.

Figure 7. Forest plot of comparison: dexamethasone vs. control. Outcome: incidence of PONV (Fujii [16] is excluded).
by Wang et al. showed no further effect by increasing the total dose from 5 mg to 10 mg [15], which is also confirmed by a meta-analysis by Henzi et al. [33]. The possible reason is that the maximal anti-emetic effect of dexamethasone reaches a ceiling at a lower dosing level. However, the studies by Lee et al. and Fuji et al. concluded that higher doses of dexamethasone are more effective at reducing symptoms than are lower doses [8 mg vs. 5 mg; 8 mg vs. 4 mg] [15,17]. Because of the limited number of included RCTs, we did not apply a further layer of analysis for the effect of different dosage of dexamethasone.

In our included studies, no postoperative wound infections or steroid-related adverse events were noted. A previous study evaluated the complications of preoperative administration of dexamethasone, and found no harm to patients [34]. Furthermore, several studies evaluating the administration of corticosteroid for other (oral or orthognathic) surgery found no significant difference in the risk of wound infection [35,36]. Thus, single-dose administration of dexamethasone seems to be safe in otherwise healthy patients undergoing thyroidectomy.

**Limitation**

Our meta-analysis has several limitations. First, there was significant heterogeneity in the results for the incidence and severity of PONV, as well as pain severity. Because of the small size effect and limited number of included studies, we did not apply a further layer of analysis and only performed the random-effects model analysis. Secondly, some statistical methods used in our study may be limited, such as using I² to assess the amount of heterogeneity in random-effects meta-analysis [37] and visual assessment of the funnel plot for excluding publication bias. Thirdly, although we made our best effort to get the full text of all published studies, there were still some studies that were not included in our meta-analysis due to the lack of detailed data.

**Conclusions**

This systematic review and meta-analysis suggests the following: i) A single preoperative administration of dexamethasone in patients undergoing thyroidectomy is safe and reduces the incidence and severity of PONV; ii) Pain severity and analgesic consumption cannot be reduced by a single preoperative administration of dexamethasone; and iii) The effect of different dosage of dexamethasone is unclear, so further studies with a larger sample size using a higher dexamethasone dose are needed to analyze its beneficial effect on postoperative pain severity and analgesic consumption.

**Statement**

No current funding sources for this study.

**References:**

1. Fujii Y: The benefits and risks of different therapies in preventing postoperative nausea and vomiting in patients undergoing thyroid surgery. Curr Drug Saf, 2008; 3(1): 27–34
2. Cohen MM, Duncan PG, DeBoer DP, Tweed WA: The postoperative inter-intravenous use of dexamethasone for nausea and vomiting. Anesth Analg, 1994; 78(1): 7–16
3. Fuji Y, Saibot Y, Tanaka H, Toyooka H: Prophylactic antiemetic therapy with granisetron in women undergoing thyroidectomy. Br J Anaesth, 1998; 81(4): 526–28
4. Apfel CC, Laara E, Koivuranta M et al: A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology, 1999; 91(3): 693–700
5. Thompson DP, Ashley FL: Face-lift complications: a study of 922 cases performed in a 6-year period. Plast Reconstr Surg, 1978; 61: 40–49
6. Apfel CC, Kranke P, Eberhart LH: Comparison of surgical site and patient's history with a simplified risk score for the prediction of postoperative nausea and vomiting. Anesthesia, 2004; 59(11): 1078–82
7. Voigt M, Fröhlich CW, Hüttel C et al: Prophylaxis of intra- and postoperative nausea and vomiting in patients during cearean section in spinal anesthesia. Med Sci Monit, 2013; 19: 993–1000
8. Janicki PK: Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit, 2005; 11(10): RA322–28
9. McKean S, Kochilas L, Kelleher R, Dockery M: Use of intravenous steroids at induction of anaesthesia for adult tonsillectomy to reduce post-operative nausea and vomiting and pain: a double-blind randomized controlled trial. Clin Otolaryngol, 2006; 31: 36–40
10. Holte K, Kehlet H: Perioperative single-dose glucocorticoid administration: pathophysiologic effects and clinical implications. J Am Coll Surg, 2002; 195(5): 694–712
11. Bisgaard T, Klaraskov B, Kehlet H, Rosenberg J: Preoperative dexamethasone improves surgical outcome after laparoscopic cholecystectomy: a randomized double-blind placebo-controlled trial. Ann Surg, 2003; 238(5): 651–60
12. Moran RE, Castro AF: The superior laryngeal nerve in thyroid surgery. Ann Surg, 1951; 134(6): 1018–21
13. Smith DB NE, Rustin GJ et al: Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet, 1991; 338: 487–90
14. Aapro MS, Alberts DS: Dexamethasone as an antiemetic in patients treated with cisplatin. N Engl J Med, 1981; 305: 520
15. Lee Y, Lin PC, Lai HY et al: Prevention of PONV with dexamethasone in female patients undergoing desflurane anesthesia for thyroidectomy. Acta Anaesthesiol Sin, 2001; 39(4): 151–56
16. Wang JJ, Ho ST, Lee SC et al: The prophylactic effect of dexamethasone on postoperative nausea and vomiting in women undergoing thyroidectomy: a comparison of droperidol with saline. Anesth Analg, 1999; 89(1): 200–3
17. Fuji Y, Nakayama M: Efficacy of dexamethasone for reducing postoperative nausea and vomiting and analgesic requirements after thyroidectomy. Otolaryngol Head Neck Surg, 2007; 136(2): 274–77
18. Worni M, Schudel HH, Seiffert E et al: Randomized controlled trial on single dose steroid before thyroidectomy for benign disease to improve postoperative nausea, pain, and vocal function. Ann Surg, 2008; 248(6): 1060–66
19. Feroci F, Rettori M, Borrelli A et al: Dexamethasone prophylaxis before thyroidectomy to reduce postoperative nausea, pain, and vocal dysfunction: a randomized clinical controlled trial. Head Neck, 2011; 33(6): 840–46
20. Doksrod S, Sagen O, Nostdahl T, Raeder J: Dexamethasone does not re-duce pain or analgesic consumption after thyroid surgery: a prospective, randomized trial. Acta Anaesthesiol Scand, 2012; 56(4): 513–19
21. Chen CC, Siddiqui FJ, Chen TL et al: Dexamethasone for prevention of post-operative nausea and vomiting in patients undergoing thyroidectomy: meta-analysis of randomized controlled trials. World J Surg, 2012; 36(1): 61–68
22. Barros A, Vale CP, Oliveira FC et al: Dexamethasone effect on postoperative pain and tramadol requirement after thyroidectomy. Pharmacology, 2013; 91(3–4): 153–57
23. Moher D, Cook DJ, Eastwood S et al: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet, 1999; 354(9193): 1896–900
24. Bero L, Rennie D: The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA, 1995; 274(24): 1935–38
25. Jadad AR, Moore RA, Carroll D et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controll Clin Trials, 1996; 17(1): 1–12
26. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version. 2009
27. van Tulder M, Furlan A, Bombardier C, Bouter L: Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine, 2003; 28(12): 1290–99
28. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis de-tected by a simple, graphical test. BMJ,1997; 315(7109): 629–34
29. Apfel CC, Roewer N: [Postoperative nausea and vomitting.] Anaesthesist, 2004; 53: 377–89, quiz 390–91 [in German]
30. Sonner JM, Hynson JM, Clark O, Katz JA: Nausea and vomiting following thyroid and parathyroid surgery. J Clin Anesth, 1997; 9(5): 398–402
31. Watcha MF, White PF: Postoperative nuasea and vomiting: its etiology, treatment, and prevention. Anesthesiology, 1992; 77(1): 162–84
32. De Oliveira GS Jr, Almeida MD, Benzon HT, McCarthy RI: Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology, 2011; 115(3): 575–88
33. Häni I, Walder B, Tramer MR: Dexamethasone for the prevention of post-operative nausea and vomiting: a quantitative systematic review. Anesth Analgesia, 2000; 90(1): 186–94
34. Sauerland S, Nagelschmidt M, Mallmann P, Neugebauer EA: Risks and ben-efits of preoperative high dose methylprednisolone in surgical patients: a systematic review. Drug Saf, 2000; 23(5): 449–61
35. Dan AE, Thygesen TH, Pinholt EM: Corticosteroid administration in oral and orthognathic surgery: a systematic review of the literature and meta-anal-ysis. J Oral Maxillofac Surg, 2010; 68(9): 2207–20
36. Thoren H, Snall J, Kormi E et al: Does perioperative glucocorticosteroid treat-ment correlate with disturbance in surgical wound healing after treatment of facial fractures? A retrospective study. J Oral Maxillofac Surg, 2009; 67(9): 1884–88
37. Knapp G, Biggerstaff BJ, Hartung J: Assessing the amount of heterogene-ity in random-effects meta-analysis. Biom J, 2006; 48(2): 271–85